Chemotherapy

1. Front Matter

   Pages i-xii

   PDF

2. Advances in Cancer Chemotherapy

   • Emil Frei III

   Pages 1-17

3. Experimental Basis of Cancer Chemotherapy

   • Norbert Brock

   Pages 19-50

4. New Leads Towards Antitumor Selectivity in Therapeutics

   • Enrico Mihich

   Pages 51-55

5. An Experimental Approach to Increase Selective Tumour Toxicity of Methotrexate

   • M. H. N. Tattersall

   Pages 57-68

6. Alterations in Intracellular Cyclic AMP as a Potential Form of Anti-Tumour Chemotherapy

   • M. J. Tisdale, B. J. Phillips

   Pages 69-74

7. The Drug-Carrier Potential of Liposomes in Cancer Chemotherapy

   • Gregory Gregoriadis

   Pages 75-82

8. Significance of Prostaglandins in Tumour Growth

   • Jennifer A. C. Sykes

   Pages 83-88

9. Oestrogen Binding as a Predictive Test for DMBA-Induced Tumour Response to Tamoxifen Therapy

   • V.C. Jordan, T. Jaspan

   Pages 89-94

10. Action of Anticancer Drugs on the Cell Cycle. Chromosome Damage and Differential Stage Sensitivity

    • David Scott

    Pages 95-103

11. Adriamycin Metabolism in Man

    • Nicholas R. Bachur

    Pages 105-111

12. Pharmacokinetics of Anticancer Drugs

    • Wolfgang Sadée

    Pages 113-117

13. Pharmacokinetics and Metabolism of Anticancer Drugs

    • Ti Li Loo

    Pages 119-127

14. The Activity of New Drugs Against Mouse Tumours

    • John M. Venditti, Mary K. Wolpert-DeFilippes

    Pages 129-147

15. Platinum Complexes as Anti-Cancer Drugs

    • M.J. Cleare

    Pages 149-157

16. Streoptozotocin, Chlorozotocin and Related Nitrosourea Antitumour Agents

    • Phillip S. Schein, Tom Anderson, Mary G. McMenamin, Joan Bull

    Pages 159-166

17. Analogues and Metabolites of Cyclophosphamide

    • K. Norpoth

    Pages 167-181

18. ICRF 159 and Other Bisdioxopiperazines

    • K. Hellmann

    Pages 183-186

19. Biological Basis of Radiosensitization by Hypoxic-Cell Radiosensitizers

    • G. E. Adams, J. Denekamp, J. E. Fowler

    Pages 187-206

20. Bleomycin and Radiotherapy

    • J. Rygard, Hanne S. Hansen

    Pages 207-210

The International Society of Chemotherapy meets every two years to review progress in chemotherapy of infections and of malignant disease. Each meeting gets larger to encompass the extension of chemotherapy into new areas. In some instances, expansion has been rapid, for example in cephalosporins, pen­ icillins and combination chemotherapy of cancer - in others slow, as in the field of parasitology. New problems of resistance and untoward effects arise; reduction of host toxicity without loss of antitumour activity by new substances occupies wide attention. The improved results with cancer chemotherapy, es­ pecially in leukaemias, are leading to a greater prevalence of severe infection in patients so treated, pharmacokinetics of drugs in normal and diseased subjects is receiving increasing attention along with related problems of bioavailability and interactions between drugs. Meanwhile the attack on some of the major bacterial infections, such as gonorrhoea and tubercu­ losis, which were among the first infections to feel the impact of chemotherapy, still continue to be major world problems and are now under attack with new agents and new methods. From this wide field and the 1,000 papers read at the Congress we have produced Proceedings which reflect the variety and vigour of research in this important field of medicine. It was not possible to include all of the papers presented at the Congress but we have attempted to include most aspects of cur­ rent progress in chemotherapy.

• cancer
• chemotherapy
• kinetics
• pharmacokinetics
• research
• resistance
• toxicity

• Westminster Hospital and Imperial Cancer Research Fund, UK

  K. Hellmann

• Chester Beatty Research Institute, UK

  T. A. Connors

Policies and ethics